<DOC>
	<DOCNO>NCT00268619</DOCNO>
	<brief_summary>Study objective : - To demonstrate acute administration ramipril control inflammation process patient high-risk Acute Coronary Syndrome ( ACS ) assess high sensitivity C-reactive protein blood level . - To demonstrate normalization blood glucose level intravenous insulin improve inflammation process acute phase ACS assess Tumor necrosis factor alpha blood level .</brief_summary>
	<brief_title>FOCUS : Focus On Coronary Unstable Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<criteria>Subject either childbearing potential pregnant agrees use contraceptive measure duration study Subjects present within 12 hour last episode chest pain : An accelerate pattern anginal pain A prolonged recurrent anginal pain rest minimal effort AND Evidence myocardial ischemia ECG manifest least one follow ECG criterion : new persistent transient STsegment depression OR transient reversible STsegment elevation new persistent transient Twave inversion OR Abnormal cardiac marker define : CKMB great upper limit normal Troponin T I level great upper limit normal . Known suspected pregnancy actively breastfeed Female childbearing potential use planning use reliable method contraception Treatment Hormone Replacement Therapy time randomization Angina precipitate obvious provoke factor Heart Failure define know ejection fraction less equal 40 % NYHA ( New York Heart Association ) class III pr IV Type I Diabetes Mellitus Type II diabetes require insulin therapy Hyperkaliemia Acute chronic inflammatory , collagen tissue disease , autoimmune disease cancer and/or require use antiinflammatory antineoplastic agent time randomization Use nonsteriodal antiinflammatory agent , coxibs , antineoplasic agent within last 7 day Use oral intravenous steroidal agent last 7 day study entry Uncontrolled hypertension Systolic pressure &lt; 100 mmHg randomization Likelihood require treatment study period drug permit protocol Treatment investigational product device last 4 week Previous participation trial History hypersensitivity , allergy , intolerance AngiotensinConverting Enzyme inhibitor . Severe cardiovascular disease require urgent therapy Severe comorbid condition History cancer know disease free , exception basal cell carcinoma skin Clinically important systemic disorder Impaired hepatic function Clinically important chronic acute renal failure History drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>